This provider's $128.6M in total Medicare payments ranks in the 99th percentile of Clinical Laboratory providers nationally.
Medicare payments to this provider grew 218% from 2014 to 2023.
AI-generated analysis based on Medicare payment data.
Notable: Payments increased 98% in 2021
Year-over-year payment surges can indicate changes in practice volume, new services, or billing pattern shifts.
Average per-service amounts submitted by the provider compared to what Medicare actually paid — the gap represents the markup.
| Year | Avg Submitted | Avg Paid | Markup Ratio | Gap per Service | Total Payments | Services | Beneficiaries |
|---|---|---|---|---|---|---|---|
| 2014 | $23.61 | $22.20 | 1.06x | $1.41 | $5.6M | 252.6K | 31 |
| 2015 | $24.54 | $23.60 | 1.04x | $0.94 | $8.8M | 371.7K | 36 |
| 2016 | $107.91 | $77.45 | 1.39x | $30.46 | $7.3M | 93.7K | 20 |
| 2017 | $88.89 | $72.91 | 1.22x | $15.98 | $13.0M | 178.4K | 15 |
| 2018 | $87.90 | $68.71 | 1.28x | $19.19 | $14.4M | 209.3K | 13 |
| 2019 | $90.04 | $66.95 | 1.34x | $23.09 | $11.3M | 169.4K | 15 |
| 2020 | $85.38 | $64.51 | 1.32x | $20.87 | $8.9M | 138.6K | 15 |
| 2021 | $101.12 | $78.16 | 1.29x | $22.96 | $17.7M | 226.7K | 18 |
| 2022 | $43.21 | $40.33 | 1.07x | $2.88 | $23.7M | 588.7K | 28 |
| 2023 | $31.96 | $31.00 | 1.03x | $0.96 | $17.8M | 575.3K | 41 |
| Code | Description | Services | Payments | Avg/Service | Markup |
|---|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 137.1K | $32.8M | $239.16 | 1.23x |
| 0117U | Analysis of 11 biochemical substances in urine to evaluate likelihood of atypical biochemical function associated with pain | 20.7K | $17.2M | $831.25 | 1.01x |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 55.8K | $10.8M | $194.12 | 1.30x |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 920.8K | $10.8M | $11.76 | 1.02x |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 122.8K | $9.7M | $79.15 | 1.33x |
| 80307 | Testing for presence of drug, by chemistry analyzers | 142.2K | $9.4M | $66.36 | 1.38x |
| 82542 | Chemical analysis using chromatography technique | 165.6K | $4.0M | $23.97 | 1.07x |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 22.0K | $3.4M | $154.03 | 1.53x |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 24.7K | $2.8M | $112.00 | 1.69x |
| 83789 | Mass spectrometry (laboratory testing method) | 109.8K | $2.6M | $23.90 | 1.04x |
| G0431 | Drug screen, qualitative; multiple drug classes by high complexity test method (e.g., immunoassay, enzyme assay), per patient encounter | 26.5K | $2.6M | $97.06 | 1.02x |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within | 99.1K | $2.5M | $24.90 | 1.00x |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 87.6K | $2.0M | $23.40 | 1.07x |
| 83921 | Organic acid level | 91.8K | $2.0M | $21.25 | 1.12x |
| 84207 | Vitamin b-6 level | 50.3K | $1.7M | $33.67 | 1.20x |
| G0479 | Drug tests(s), presumptive, any number of drug classes; any number of devices or procedures by instrumented chemistry analyzers utilizing immunoassay, enzyme assay, TOF, MALDI, LDTD, DESI, DART, GHPC, GC mass spectrometry), includes sample validation when | 18.6K | $1.4M | $77.41 | 1.25x |
| 82486 | Chemical analysis | 56.6K | $1.4M | $24.11 | 1.02x |
| 83918 | Organic acids level | 50.0K | $1.1M | $22.66 | 1.05x |
| 83090 | Homocysteine (amino acid) level | 53.9K | $1.1M | $20.53 | 1.22x |
| G6056 | Opiate(s), drug and metabolites, each procedure | 40.2K | $1.0M | $25.95 | 1.02x |
This provider submits charges 1.19 times higher than what Medicare actually pays.
A markup ratio of 1.19x means for every $100 Medicare pays, this provider initially charges $119. This is lower than the national average.
Always verify provider credentials and location before scheduling appointments. This data reflects Medicare payments and may not include all practice locations.
Other Clinical Laboratory providers in KY for peer comparison.
| Provider | Location | Total Payments | Status |
|---|---|---|---|
| Dx Solutions, Llc | Nicholasville, KY | $43.5M | ✓ Clear |
Share this provider's Medicare payment information
Last Updated: February 2026 (data through 2023, the latest CMS release)
Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.
Believe this data is inaccurate? Dispute this data